Alta Partners Management Company, L.P.

Key Holdings

The portfolio is dominated by a single position, Tyra Biosciences Inc., which is valued at $100.52 million and consists of 3.82 million shares. This holding represents nearly the entirety of the fund's capital (97.03%), indicating an exceptionally strong bullish stance on the company. The secondary holding, Vir Biotechnology Inc. (VIR), is valued at $3.07 million comprising 510,000 shares. While this is a negligible weight in the current portfolio (2.97%), it serves as the only other diversifying asset. The massive disparity in allocation between these two positions suggests that Alta Partners views Tyra Biosciences as a primary driver of alpha, while Vir Biotechnology plays a minor, perhaps experimental or residual, role in the strategy.